High prevalence of double Plasmodium falciparum dhfr mutations at codons 108 and 59 in the Sistan-Baluchistan province, Iran by Zakeri, S et al.
1828 • JID 2003:187 (1 June) • CORRESPONDENCE
Table 1. Frequencies of Plasmodium falciparum dhfr and dhps genotypes of malaria patients in the Sistan-Baluchistan Province,
Iran.
Codon analysis
scheme
(Pfdhfr/Pfdhps)
Total
no. of
patients F score (95% CI)
Genotype, no. of patients
108R 51S
59S 437S
540S
108R 51S
59R/S 437S
540S
108R/S 51S
59R 437S
540S
108R 51S
59R 437S
540S
108R 51R/S
59R 437S
540S
108R 51S
59R 437R/S
540S
108R 51S
59R 437R
540S
108R 51R/S
59R 437R/S
540S
Single/wild 3 0.030 (0.062–0.854) 3 0 0 0 0 0 0 0
Double/wild 78 0.772 (0.0690–0.854) 0 2 4 72 0 0 0 0
Triple/wild 4 0.040 (0.011–0.098) 0 0 0 0 4 0 0 0
Double/single 15 0.149 (0.079–0.218) 0 0 0 0 0 14 1 0
Triple/single 1 0.009 (0.003–0.054) 0 0 0 0 0 0 0 1
NOTE. The codon analysis scheme follows the proposal of Kublin et al. [3]. CI, confidence interval; R, resistance-associated allele; R/S, mixed allele; S,
sensitivity-associated allele.
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High Prevalence of Double
Plasmodium falciparum
dhfr Mutations at Codons
108 and 59 in the Sistan-
Baluchistan Province, Iran
To the Editor—In Iran, transmission of
Plasmodium falciparum malaria mainly
occurs in the Sistan-Baluchistan province,
where 190% of the annual cases are ob-
served [1]. Chloroquine is recommend-
ed as the first-line antimalarial treatment,
and sulfadoxine-pyrimethamine (SP) is
recommended as the second-line treat-
ment. SP appears to be effective in the
region, although findings of in vivo and
in vitro resistance in some small-scale, lo-
cal drug resistance studies have already
been documented [2]. However, SP re-
sistance has been consistently reported
among Afghan refugee settlements along
the western border of Pakistan [3], a re-
gion from which human migration re-
cently has increased substantially. This
raises the concern that SP-resistant ma-
laria parasites are now invading the near-
by regions of Iran.
Mutations in the P. falciparum dhfr and
dhps genes represent a valuable tool for
epidemiological surveillance of SP resis-
tance in the region, as has been sugges-
ed elsewhere for another setting in which
malaria is endemic [4]. This is supported
by a positive correlation between muta-
tions in the dhfr and dhps genes and in
vivo SP resistance observed in a prelimi-
nary study in the Iranian coastal province
of Hormozgan [5].
To evaluate the present status of these
genes in the Sistan-Baluchistan province,
we have studied the dhfr (Ser108Asn,
Asn51Ile, and Cys59Arg) and dhps
(Ala437Gly and Lys540Glu) single-nucle-
otide polymorphism (SNP) frequencies in
101 symptomatic patients with micro-
scopically confirmed P. falciparum malaria
attending the Chahbahar Health Center.
The patients were all permanent residents
in the province; a large fraction of them
were foreigners, mostly of Afghan origin.
Blood samples were obtained after writ-
ten consent was given. DNA was extracted
through phenol-chloroform–based pro-
tocols. Established polymerase chain re-
action–restriction fragment–length poly-
morphism methods [6, 7] were performed
for the analysis of the selected SNPs.
Most patients (97%) were found to si-
multaneously carry the Ser108Asn and
Cys59Arg pyrimethamine resistance–as-
sociated mutations, mainly in “pure form”
[4], while retaining a wild-type mutation
at position 51 (table 1). The Asn51Ile mu-
tation was present in only 6 samples (6%).
A similar pattern was also found in an-
other small study of blood samples from
Pakistan [8], which suggests that a re-
gional mutation selection profile exists,
with Cys59Arg mutations preceding al-
terations in codon 51 toward the triple
mutant.
P. falciparum dhps Ala437Gly–carrying
alleles were found in 17% of the patients,
mostly in mixed form. This result was in
contrast to previous observations of no
mutations in P. falciparum dhps in a re-
gion of Pakistan [8], which suggests that
these are recent mutation selection events,
possibly specific to Iranian malaria set-
tings. Of note, the 437Gly mutation was
significantly more frequent among Irani-
ans (13/42 patients [30.9%]), compared
with patients of Afghan origin (3/54 sam-
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ples [5.5%]; ; ). The ab-2x p 9.219 P ! .01
sence of mutations at the 540 position on
P. falciparum dhps reinforces the view that
these mutations represent, in most cases,
a last step toward the quintuple mutant,
recently considered to be a landmark of
SP resistance [4].
In conclusion, these molecular data
suggest that the high prevalence of mu-
tations in the dhfr and dhps genes might
lead toward a development of SP resis-
tance in the southeastern Iranian prov-
inces. The remoteness of these regions,
which is associated with the potential
for rapid establishment of SP resistance,
stresses the need for continuing epide-
miological surveillance, including the use
of molecular methods, as proposed else-
where [4].
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